All In Biotech

Free tool

FAERS Monitor: Ingrezza

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 209241 or its brand name (Ingrezza, Valbenazine Tosylate). Reports on generic versions are filed under their own applications.

Reports

25,388

Serious

6,141

24% of reports

Hospitalization

3,548

Death reported

1,314

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • drug ineffective2,780
  • somnolence2,504
  • fatigue1,699
  • tremor1,611
  • tardive dyskinesia1,537
  • fall1,149
  • dizziness968
  • death946
  • drooling926
  • dyskinesia904
  • therapeutic product effect decreased893
  • off label use697
  • anxiety689
  • hospitalisation672
  • nausea641

Reports by year received

View as table
YearReports
20171,145
20183,935
20193,742
20204,036
20216,279
20221,723
20231,170
20241,124
20251,187
20261,047

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,028,771 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
droolingSignal926128.1119.6101,036
tardive dyskinesiaSignal1,53747.745.466,458
dyskinesiaSignal90418.817.614,929
therapeutic product effect decreasedSignal89316.815.813,046
somnolenceSignal2,50410.410.021,252
tremorSignal1,6118.17.710,017
hospitalisationSignal6723.63.41,285
fallSignal1,1492.92.71,412
anxietySignal6892.01.9352
fatigue1,6991.81.7637
drug ineffective2,7801.71.7949
dizziness9681.61.5228
death9460.90.99
nausea6410.70.6107
off label use6970.70.6128

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.